NVST Envista Holdings Corp
Dental Equipment & Supplies · NYSE · SEC CIK 1757073 · Fiscal year ends 12/31
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY9.8%
TTM net income YoY4,041.2%
TTM EPS YoY4,177.8%
Revenue 3-yr CAGR3.7%
Net income 3-yr CAGR49.2%
Margins
Gross margin55.9%
Operating margin25.4%
Net margin22.0%
FCF margin8.4%
EBITDA margin29.3%
Returns
ROE20.5%
ROA11.3%
ROIC (approx.)20.0%
Asset turnover0.51x
Leverage & solvency
Liabilities / assets45.0%
Debt / equity0.46x
Current ratio2.45x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.48x
Accruals ratio5.9%
Payout ratio—
Capex / revenue2.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $2.72B | $2.51B |
| Cost of revenue | $1.23B | $1.14B |
| Gross profit | $1.49B | $1.37B |
| R&D expense | $114.00M | $99.10M |
| SG&A expense | $1.16B | $1.16B |
| Operating income | $216.10M | -$1.04B |
| Pretax income | $177.20M | -$1.08B |
| Income tax | $130.20M | $33.90M |
| Net income | $47.00M | -$1.12B |
| EBITDA | $332.10M | -$915.10M |
| EPS (basic) | 0.28 | -6.50 |
| EPS (diluted) | 0.28 | -6.50 |
| Weighted avg. shares (diluted) | 169.20M | 172.20M |
| Balance sheet | ||
| Cash & equivalents | $1.21B | $1.07B |
| Receivables | $429.60M | $363.00M |
| Inventory | $288.10M | $241.00M |
| Current assets | $2.03B | $1.79B |
| PP&E, net | $296.80M | $277.00M |
| Goodwill | $2.36B | $2.26B |
| Intangibles | $627.20M | $649.90M |
| Total assets | $5.68B | $5.35B |
| Current liabilities | $852.60M | $878.70M |
| Short-term debt | $0 | $116.00M |
| Long-term debt | $1.45B | $1.28B |
| Total debt | $1.45B | $1.39B |
| Total liabilities | $2.57B | $2.42B |
| Shareholders' equity | $3.11B | $2.93B |
| Net debt | $236.60M | $325.20M |
| Shares outstanding | 163.80M | 172.20M |
| Cash flow statement | ||
| Operating cash flow | $275.70M | $336.50M |
| Capital expenditure | $45.30M | $33.80M |
| Free cash flow | $230.40M | $302.70M |
| Investing cash flow | -$51.10M | -$54.60M |
| Financing cash flow | -$170.90M | -$103.70M |
| Depreciation & amortization | $116.00M | $123.10M |
| Stock-based compensation | $37.60M | $35.30M |
Free plan shows the latest 2 periods; Pro shows all 9 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.